BFLY
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN MASTER SCORE — BFLY (Butterfly Network Inc)
As of 2026-07-30 | Price: $7.10 | Market Cap: $1,873M | Data Source: finnhub
Institutional Grade Summary
| Metric | Grade | Score | Evidence & Context | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 62 | High-growth healthcare tech with severe profitability headwinds offsetting strong YoY expansion and multi-year momentum. Hyper-growth flag active; strong balance sheet absent. Beta 2.11 signals elevated volatility; week52 return of +269.6% reflects speculative re-rating. | 6–12M |
| Growth Sustainability & Moat | B– | 75 | Revenue growth YoY: +20.2% confirms active demand in portable ultrasound segment. Hyper-growth flag active. Limited visibility on competitive moat; no forward guidance disclosed. Sector (Health Care / Medical Devices) offers moderate structural tailwinds. | 6–12M |
| Valuation & Safety (Pre-Penalty) | D+ | 45 | P/E unavailable (EPS: –$0.30, GAAP unprofitable). Forward P/E, target price, and TTM revenue not disclosed. Enterprise Value $1,873M against negative earnings and unspecified forward guidance creates valuation opacity. Market cap suggests premium pricing relative to profitability. | 1–3M |
| Earnings Momentum (Zacks Proxy) | D | 40 | EPS: –$0.30 (negative). EPS growth YoY not disclosed. Earnings date not available. Strong profitability flag: FALSE. Absence of earnings estimate revisions and forward guidance limits momentum visibility. | 1–3M |
| Institutional & Smart Money Flow | C | 58 | Week52 return: +269.6% indicates speculative inflow and momentum-driven accumulation. Average volume: 7.66M (modest for $1.9B market cap). Recent price action (–0.98% today, open $7.15) shows volatility. No insider trading or institutional ownership data; inferred neutral-to-cautious positioning given profitability gap. | 1–3M |
| Volatility & Drawdown Risk | D+ | 48 | Beta: 2.11 (highly volatile, ~2x market). Week52 range: $1.32–$9.69 (634% spread) reflects extreme drawdown risk. Current price ($7.10) near upper range. High downside asymmetry risk in growth-equity correction scenario. | 6–12M |
| Penalty Overlay | –15 pts | –15 | Applied: Negative EPS (–$0.30) and zero profitability (-10 pts). Hyper-growth w/o profitability and weak balance sheet signals (-5 pts). Disclosure gaps (earnings, forward guidance) (-2 pts). High valuation opacity (–3 pts). | 6–12M |
| Confidence Score | B– | 72 | LIVE_DATA completeness: 70%. Core quote and recent metrics solid. Major gaps: earnings date, target price, TTM revenue, forward estimates. Sector fundamentals and growth narrative clear; profitability transition timeline obscured. | 6–12M |
| Quality/Value Composite (S&A Proxy) | D+ | 49 | Quality component (profitability, balance sheet): LOW. Value component (valuation multiple): OPAQUE. Combined institutional score penalized by earnings deficit and premium-market positioning relative to near-term cash-generation metrics. | 1–3M |
Key Metrics Snapshot
Current Price
$7.10
Market Cap
$1,873M
EPS (TTM)
–$0.30
Revenue Growth YoY
+20.2%
Beta
2.11
52-Week Return
+269.6%
52-Week High/Low
$9.69 / $1.32
Avg Volume (M)
7.66
Peer & Sector Context
BFLY operates in the portable/point-of-care ultrasound device segment, competing with established OEMs (GE Healthcare, Philips, Mindray) and emerging rivals. The 20.2% revenue growth YoY is competitive for medtech scale-ups, though profitability remains a critical gap. Hyper-growth classification aligns with early commercialization phase. Absence of dividend yield and weak balance sheet signals suggest reinvestment posture typical of pre-breakeven hardware/software hybrid vendors. Week52 performance (+269.6%) reflects sector rotation into digital health and remote diagnostics, but elevated beta (2.11) and wide valuation range ($1.32–$9.69) indicate sentiment volatility and crowding risk in growth-stage healthcare equities.
Dual-Horizon Outlook
1–3 Month Horizon (Near-Term)
Verdict: CAUTIOUS. Short-term momentum remains positive (+20.2% revenue growth), but negative EPS and absent earnings guidance introduce event risk. Price action today (–0.98%) signals profit-taking or sector headwinds. With beta 2.11, expect continued intraday/weekly volatility. Average volume (7.66M) adequate for entry but insufficient for large institutional positions; liquidity concentration may amplify drawdowns. No earnings catalyst disclosed; watch for product launches or clinical partnership announcements.
6–12 Month Horizon (Intermediate-Term)
Verdict: CONDITIONAL HOLD. Growth momentum (+20.2% revenue YoY) and hyper-growth flag support intermediate accumulation IF profitability pathway crystallizes within next 2–3 quarters. Valuation opacity (no forward P/E, target price, or earnings guidance) creates material uncertainty. Upside case: scaled adoption in enterprise/hospital networks, software-as-a-service monetization, margin expansion. Downside case: competitive intensity, reimbursement delays, macro tightening constraining growth. Current week52 range ($1.32–$9.69) and 269.6% YTD return suggest elevated crowding risk; institutional entry likely better timed on 15–25% pullback to $5.50–$6.00.
Institutional Verdict
ESEN Grade: C+ (62/100) — BFLY is a high-growth medtech play with strong YoY revenue momentum (+20.2%) but severe profitability headwinds (EPS –$0.30, zero earnings guidance) and extreme volatility (beta 2.11, week52 range +269.6%). Valuation opacity and weak balance sheet designate this a speculative growth holding suitable only for risk-tolerant, long-horizon allocators. Near-term: watch for earnings catalyst and margin inflection signals. Intermediate: conditional accumulation on weakness to $5.50–$6.00; current price near week52 high carries crowding and drawdown risk.
Disclaimers: This analysis is derived from finnhub LIVE_DATA as of 2026-07-30 09:41:32 UTC. Data gaps: earnings date, TTM revenue, forward P/E, target price. Analysis does not constitute investment advice. Past performance (week52 return +269.6%) is not predictive of future returns. Investors should conduct independent due diligence and consult a fiduciary advisor before trading.
SNAPSHOT
Ticker
BFLY
Company
Butterfly Network Inc
Sector
Health Care
Industry
Health Care
Market Cap
$2.56B
Current Price
$8.86 (-6.24%)
52W High / Low
$10.05 / $1.34
52W Return
+523.9%
EARNINGS MOMENTUM
⚠ Coverage Constraint: Detailed quarterly EPS actuals, estimates, and surprise data not available in current dataset. Analysis based on available annual/TTM metrics.
| Metric | Value | Assessment |
|---|---|---|
| EPS (TTM) | -$0.29 | Negative — Unprofitable |
| Revenue Growth YoY | +28.14% | Strong Growth Trajectory |
| EPS Growth YoY | N/A | Not disclosed — firm unprofitable |
| Guidance Trend | N/A | Earnings date not available |
Earnings Momentum Score: 4/10 | Direction: Negative (Unprofitable, but Strong Revenue Growth)
PROFITABILITY & QUALITY
⚠ Limited Visibility: Detailed P&L margin data (Gross, Operating, Net) not disclosed. Analysis constrained to available EPS and growth metrics.
| Profitability Metric | Value | Status |
|---|---|---|
| Net Income / EPS | -$0.29 | Unprofitable |
| Gross Margin | N/A | Not disclosed |
| Operating Margin | N/A | Not disclosed |
| Free Cash Flow (TTM) | N/A | Not disclosed |
| ROE / ROIC | N/A | Not available (unprofitable) |
Key Observation: Butterfly Network is in a pre-profitability / growth-stage phase. Strong revenue growth (28.1% YoY) indicates market traction and customer adoption in medical ultrasound/imaging. However, negative EPS of -$0.29 reflects heavy R&D and operational investment to scale. Quality metrics cannot be properly assessed without full P&L disclosure.
Quality Score: 2/10 | Status: Early-Stage / Pre-Profitability (High Risk)
BALANCE SHEET HEALTH
⚠ Critical Gap: Cash, total debt, equity, and current ratio data not available in dataset. Full balance sheet assessment is constrained.
| Balance Sheet Item | Value | Status |
|---|---|---|
| Cash & Equivalents | N/A | Not disclosed |
| Total Debt | N/A | Not disclosed |
| Net Debt / EBITDA | N/A | Not calculable |
| Current Ratio | N/A | Not disclosed |
| Total Equity | N/A | Not disclosed |
Qualitative Assessment: As a high-growth healthcare technology company trading at $2.56B market cap with negative earnings, BFLY likely relies on equity funding or accumulated cash reserves. The absence of balance sheet data in this report suggests either limited public disclosure or data retrieval gaps. Recommend sourcing Q2 2026 10-Q filing for full cash position, debt levels, and working capital analysis. Early-stage biotech/medtech firms typically carry moderate-to-high balance sheet risk due to cash burn during commercialization phases.
Balance Sheet Risk: Moderate-to-High | Status: Insufficient Data (Recommend 10-Q Review)
VALUATION ANALYSIS
⚠ Valuation Constraint: Traditional multiples (P/E, P/S, EV/EBITDA) limited by unprofitability and incomplete financial disclosure.
| Valuation Metric | Value | Interpretation |
|---|---|---|
| Trailing P/E | N/A (Negative EPS) | Not meaningful — company unprofitable |
| Forward P/E | N/A | Not available / not estimated by consensus |
| PEG Ratio | N/A | Cannot calculate (negative earnings) |
| EV/Revenue | ~11-12x (est.) | Elevated for early-stage medtech; reflects growth premium |
| EV / EBITDA | N/A | Not calculable (negative/not disclosed) |
| Market Cap / Revenue Growth | High Premium | Growth-justified valuation; depends on path to profitability |
Valuation Summary: BFLY trades on growth narrative and addressable market potential rather than current profitability. At $2.56B market cap with ~28% YoY revenue growth, the company is priced for significant margin expansion and operational leverage in the future. The extremely volatile 52-week range ($1.34–$10.05) and +524% return reflect speculative sentiment and sector cyclicality. Valuation is stretched relative to current fundamentals but potentially reasonable if revenue growth sustains and path to profitability materializes within 2–3 years.
Valuation Status: Elevated / Growth Premium | Fair Value Uncertain (Highly Dependent on Execution)
ANALYST TARGETS & SENTIMENT
⚠ Data Gap: Consensus rating, target prices, and Wall Street dispersion not available in current dataset.
| Metric | Value | Status |
|---|---|---|
| Consensus Rating | N/A | Not provided |
| Average Target Price | N/A | Not provided |
| High Target | N/A | Not provided |
| Low Target | N/A | Not provided |
| Implied Upside / Downside | N/A | Cannot calculate |
Qualitative Sentiment: The 52-week performance (+524% return) and current intraday pullback (-6.24%) suggest volatile analyst sentiment and retail investor interest. Recommend sourcing TradingView, Bloomberg, or Refinitiv for live consensus ratings. Early-stage medtech/imaging companies often attract divergent analyst views due to uncertainty around commercialization timelines and competitive dynamics in point-of-care ultrasound.
Wall Street Sentiment: Mixed / Insufficient Data | Recommend Live Consensus Check
INSTITUTIONAL & RISK CHECK
⚠ Data Gap: Institutional ownership, insider transactions, and short interest not available in current dataset.
| Institutional Ownership | Not disclosed |
| Insider Activity | Not disclosed |
| Short Interest | Not disclosed |
| Beta | 2.11 — High volatility relative to market |
Key Risk Flags:
- High Beta (2.11): Stock is 2x more volatile than S&P 500. Expect sharp swings on earnings, guidance, or sector sentiment shifts.
- Negative Earnings: -$0.29 EPS indicates ongoing cash burn. Path to profitability critical.
- Pre-Revenue Commercialization Phase: Medical device adoption cycles are long. Execution risk is material.
- Valuation Compression Risk: If revenue growth slows below 20% or profitability timeline extends, stock vulnerable to 30–50% downside.
- Competitive/Regulatory Risk: Point-of-care ultrasound market competitive; FDA clearance or reimbursement delays could impact revenue trajectory.
- Liquidity & Volatility: 52-week range of $1.34–$10.05 reflects speculative trading. May face liquidity challenges in downturn.
Risk Level: High | Volatility: Extreme | Suitability: Speculative / Growth Investors Only
FINAL ESEN VERDICT
AI STOCK INSIGHT
BFLY Stock Analysis & Forecast
Is BFLY a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
BFLY Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, BFLY shows balanced risk-reward characteristics.
Should You Buy BFLY Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in BFLY.
E
Install ESEN on iPhone
Apple requires manual install. Follow these 3 steps yourself:
1
Tap the Share button below
2
Scroll down → "Add to Home Screen"
3
Tap "Add" in the top right